Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Snowsill, T."" wg kryterium: Autor


Wyświetlanie 1-3 z 3
Tytuł :
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Autorzy :
Tikhonova IA; Peninsula Technology Assessment Group (PenTAG), University of Exeter, South Cloisters 3.09, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK. .
Huxley N; Monash University, Melbourne, VIC, Australia.
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter, South Cloisters 3.09, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK.
Crathorne L; Roboleo Ltd, York, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, South Cloisters 3.09, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK.
Napier M; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, South Cloisters 3.09, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK.
Pokaż więcej
Źródło :
PharmacoEconomics [Pharmacoeconomics] 2018 Jul; Vol. 36 (7), pp. 837-851.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*economics
Camptothecin/*analogs & derivatives
Cetuximab/*economics
Colonic Neoplasms/*economics
Colorectal Neoplasms/*economics
Cost-Benefit Analysis/*statistics & numerical data
Panitumumab/*economics
Antibodies, Monoclonal, Humanized/economics ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/economics ; Camptothecin/therapeutic use ; Cetuximab/therapeutic use ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/genetics ; Colonic Neoplasms/secondary ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/secondary ; Female ; Fluorouracil/economics ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/economics ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Models, Economic ; Organoplatinum Compounds/economics ; Organoplatinum Compounds/therapeutic use ; Panitumumab/therapeutic use ; Proto-Oncogene Proteins p21(ras)/genetics ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic/statistics & numerical data ; Survival Analysis
SCR Protocol :
Folfox protocol; IFL protocol
Czasopismo naukowe
Tytuł :
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Autorzy :
Huxley N; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Crathorne L; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Tikhonova I; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Briscoe S; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Peters J; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Bond M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Napier M; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2017 Jun; Vol. 21 (38), pp. 1-294.
Typ publikacji :
Journal Article; Review; Systematic Review
MeSH Terms :
Treatment Outcome*
Antibodies, Monoclonal/*administration & dosage
Antibodies, Monoclonal/*economics
Antineoplastic Agents/*administration & dosage
Antineoplastic Agents/*economics
Antineoplastic Agents, Immunological/*administration & dosage
Antineoplastic Agents, Immunological/*economics
Cetuximab/*administration & dosage
Cetuximab/*economics
Colorectal Neoplasms/*drug therapy
Neoplasm Metastasis/*drug therapy
Cost-Benefit Analysis ; Female ; Humans ; Male ; Panitumumab ; Technology Assessment, Biomedical
Czasopismo naukowe
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies